From 02e4aca1f77730bba231cda900d02213506b00a4 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 20 Mar 2026 04:46:15 +0000 Subject: [PATCH 1/4] extract: 2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026 Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...astructure connects screening to action.md | 6 ++++ ...onciliation-bill-healthcare-cuts-2026.json | 32 +++++++++++++++++++ ...econciliation-bill-healthcare-cuts-2026.md | 16 +++++++++- 3 files changed, 53 insertions(+), 1 deletion(-) create mode 100644 inbox/queue/.extraction-debug/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.json diff --git a/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md b/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md index d58c60e37..10345bd13 100644 --- a/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md +++ b/domains/health/SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md @@ -47,6 +47,12 @@ Community health worker programs demonstrate the same payment boundary stall: on The Diabetes Care perspective challenges the 'strong ROI' claim for SDOH interventions by questioning whether produce prescriptions—a specific SDOH intervention—actually produce clinical outcomes. The observational evidence showing improvements may reflect methodological artifacts (self-selection, regression to mean) rather than true causal effects. This suggests the ROI evidence for SDOH interventions may be weaker than claimed, particularly for single-factor interventions like food provision. + +### Additional Evidence (challenge) +*Source: [[2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026]] | Added: 2026-03-20* + +The RSC's second reconciliation bill proposes site-neutral payments that would eliminate the enhanced FQHC reimbursement rates (~$300/visit vs ~$100/visit) that fund CHW programs. Combined with OBBBA's Medicaid cuts, this creates a two-vector attack on the institutional infrastructure that hosts most CHW programs. The challenge is not just documentation and operational infrastructure—the payment foundation itself is under legislative threat. Even if Z-code documentation improved and operational infrastructure was built, the revenue model that makes CHW programs economically viable within FQHCs would be eliminated by site-neutral payments. + --- Relevant Notes: diff --git a/inbox/queue/.extraction-debug/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.json b/inbox/queue/.extraction-debug/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.json new file mode 100644 index 000000000..29d92c47c --- /dev/null +++ b/inbox/queue/.extraction-debug/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "republican-site-neutral-payment-proposals-eliminate-fqhc-enhanced-rates-removing-funding-mechanism-for-community-health-worker-programs.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "obbba-medicaid-cuts-plus-site-neutral-payments-create-two-vector-attack-on-chw-infrastructure-through-enrollment-loss-and-reimbursement-collapse.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "republican-site-neutral-payment-proposals-eliminate-fqhc-enhanced-rates-removing-funding-mechanism-for-community-health-worker-programs.md:set_created:2026-03-20", + "obbba-medicaid-cuts-plus-site-neutral-payments-create-two-vector-attack-on-chw-infrastructure-through-enrollment-loss-and-reimbursement-collapse.md:set_created:2026-03-20" + ], + "rejections": [ + "republican-site-neutral-payment-proposals-eliminate-fqhc-enhanced-rates-removing-funding-mechanism-for-community-health-worker-programs.md:missing_attribution_extractor", + "obbba-medicaid-cuts-plus-site-neutral-payments-create-two-vector-attack-on-chw-infrastructure-through-enrollment-loss-and-reimbursement-collapse.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-20" +} \ No newline at end of file diff --git a/inbox/queue/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.md b/inbox/queue/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.md index 988cad01e..e72569bd3 100644 --- a/inbox/queue/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.md +++ b/inbox/queue/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.md @@ -7,9 +7,13 @@ date: 2026-01-22 domain: health secondary_domains: [] format: policy analysis -status: unprocessed +status: enrichment priority: medium tags: [reconciliation, medicaid, site-neutral-payments, rsc, second-bill, fqhc, republican] +processed_by: vida +processed_date: 2026-03-20 +enrichments_applied: ["SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -56,3 +60,13 @@ The House Republican Study Committee (RSC) unveiled a framework for a second bud PRIMARY CONNECTION: [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] WHY ARCHIVED: The second reconciliation bill adds a SECOND threat to SDOH/CHW infrastructure on top of OBBBA. Site-neutral payments specifically target FQHCs, which are the primary institutional channel for CHW programs. Together with provider tax freeze (OBBBA), this creates a compound threat to the payment infrastructure that CHW scaling requires. EXTRACTION HINT: Extract as a compound claim: OBBBA (provider tax freeze) + second bill (site-neutral) = two-vector attack on CHW infrastructure. The extractor should show how these two mechanisms interact, not treat them as independent. + + +## Key Facts +- House Republican Study Committee unveiled framework for second budget reconciliation bill in January 2026 +- Second bill proposes eliminating Medicaid and CHIP eligibility for lawfully present immigrants effective October 1, 2026 +- Site-neutral payment provisions would require Medicare and potentially Medicaid to pay same rate regardless of service delivery setting +- FQHCs currently receive approximately $300 per visit vs ~$100 in physician offices +- 43% of FQHC revenue comes from Medicaid +- RSC represents most conservative House Republican faction +- Site-neutral payments likely to survive Senate Byrd Rule as significant budgetary provision -- 2.45.2 From 024ff0bd29fbd5db8222f54f8884798f196e1d9a Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 20 Mar 2026 04:58:21 +0000 Subject: [PATCH 2/4] pipeline: archive 1 source(s) post-merge Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...econciliation-bill-healthcare-cuts-2026.md | 58 +++++++++++++++++++ 1 file changed, 58 insertions(+) create mode 100644 inbox/archive/health/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.md diff --git a/inbox/archive/health/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.md b/inbox/archive/health/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.md new file mode 100644 index 000000000..3395e3b75 --- /dev/null +++ b/inbox/archive/health/2026-03-20-ccf-second-reconciliation-bill-healthcare-cuts-2026.md @@ -0,0 +1,58 @@ +--- +type: source +title: "RSC Pushes Second Reconciliation Bill January 2026 — More Medicaid Cuts and Site-Neutral Payments" +author: "Georgetown Center for Children and Families" +url: https://ccf.georgetown.edu/2026/01/22/house-republican-study-committee-pushes-for-second-budget-reconciliation-bill-and-more-damaging-medicaid-cuts/ +date: 2026-01-22 +domain: health +secondary_domains: [] +format: policy analysis +status: processed +priority: medium +tags: [reconciliation, medicaid, site-neutral-payments, rsc, second-bill, fqhc, republican] +--- + +## Content + +The House Republican Study Committee (RSC) unveiled a framework for a second budget reconciliation bill in January 2026, following the OBBBA enacted July 4, 2025. + +**Key healthcare proposals in the second bill:** + +**Medicaid coverage restrictions:** +- Eliminate Medicaid and CHIP eligibility for lawfully present immigrants (refugees, asylees, trafficking victims, domestic violence victims, humanitarian parolees) +- Would take effect October 1, 2026 + +**Payment reform:** +- Site-neutral hospital payments — would require Medicare and potentially Medicaid to pay the same rate for services regardless of where they're provided (hospital outpatient vs. physician office vs. FQHC) +- This specifically threatens FQHCs, which receive enhanced per-visit payment rates under current law +- FQHC payment rates are what fund CHW programs and integrated social services in community health centers + +**Senate Byrd Rule constraints:** +- For Senate passage, provisions must have direct and more-than-incidental budgetary impact +- Drug pricing reforms, PBM policies, Medicaid payment changes are most likely to survive Byrd Rule +- Site-neutral payments are a significant budgetary provision and would likely survive + +**Context:** +- This is IN ADDITION TO OBBBA, not instead of it +- The political trajectory is escalating cuts, not stabilizing +- RSC represents the most conservative House Republican faction — this is the direction the party is pushing + +## Agent Notes + +**Why this matters:** The second reconciliation bill adds a specific mechanism that directly threatens CHW programs: site-neutral payments. FQHCs are the primary institutional home for CHW programs in the US, receiving ~$300/visit vs. ~$100/visit in physician offices. Site-neutral would collapse this differential. The March 18 session identified FQHCs as critical to CHW scaling (43% of FQHC revenue comes from Medicaid). Site-neutral + OBBBA Medicaid cuts creates a compound threat to the only institutional channel that has scaled CHW programs. + +**What surprised me:** The second bill is being pushed without waiting to see the implementation results of OBBBA. The policy acceleration suggests the healthcare cuts are ideological/fiscal, not evidence-based. The RSC framework doesn't engage with any of the health outcomes literature (Annals study: 16,000 preventable deaths) — the cuts are proceeding regardless. + +**What I expected but didn't find:** Any VBC or prevention-oriented provisions in the RSC framework. There is nothing in the second bill that creates positive health incentives. It's entirely about cutting coverage and payments. + +**KB connections:** +- Extends the OBBBA coverage loss story — the second bill adds site-neutral FQHC threat on top of Medicaid enrollment loss +- Directly threatens the CHW infrastructure that the March 18 session identified as most RCT-validated non-clinical intervention +- Connects to healthcare is a complex adaptive system requiring simple enabling rules — the opposite of what these cuts are doing + +**Extraction hints:** The site-neutral FQHC threat is the specific extractable claim. Something like: "Republican site-neutral payment proposals would eliminate FQHCs' enhanced per-visit payment differential, removing the funding mechanism that makes community health worker programs economically viable within the institution that hosts most of them." + +## Curator Notes +PRIMARY CONNECTION: [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] +WHY ARCHIVED: The second reconciliation bill adds a SECOND threat to SDOH/CHW infrastructure on top of OBBBA. Site-neutral payments specifically target FQHCs, which are the primary institutional channel for CHW programs. Together with provider tax freeze (OBBBA), this creates a compound threat to the payment infrastructure that CHW scaling requires. +EXTRACTION HINT: Extract as a compound claim: OBBBA (provider tax freeze) + second bill (site-neutral) = two-vector attack on CHW infrastructure. The extractor should show how these two mechanisms interact, not treat them as independent. -- 2.45.2 From aa6751e0299856fe684c1cc9710e7025a3237d15 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 20 Mar 2026 04:50:23 +0000 Subject: [PATCH 3/4] extract: 2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...t cost impact inflationary through 2035.md | 6 ++++ ...just-clinical-factors-drive-persistence.md | 6 ++++ ...aglutide-india-patent-expiry-generics.json | 32 +++++++++++++++++++ ...emaglutide-india-patent-expiry-generics.md | 21 +++++++++++- 4 files changed, 64 insertions(+), 1 deletion(-) create mode 100644 inbox/queue/.extraction-debug/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 9c63d8641..958fa002f 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -125,6 +125,12 @@ If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg rega Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself. + +### Additional Evidence (challenge) +*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20* + +India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index 0c35f6498..914b402ef 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -49,6 +49,12 @@ The Trump Administration deal establishes a $50/month out-of-pocket maximum for Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects, but the sample is biased toward higher-income employed populations. The fact that even in this relatively advantaged cohort, adherence is the key determinant of cost-effectiveness supports the claim that affordability barriers in lower-income populations would be even more binding. + +### Additional Evidence (extend) +*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20* + +OBBBA work requirements threaten to remove ~10M from Medicaid coverage precisely when international GLP-1 prices are dropping 50-90% but US prices remain patent-protected at $1,300/month through 2033. This creates structural access failure where coverage loss and price compression move in opposite directions for the population with highest metabolic disease burden. + --- Relevant Notes: diff --git a/inbox/queue/.extraction-debug/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.json b/inbox/queue/.extraction-debug/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.json new file mode 100644 index 000000000..0af0a198e --- /dev/null +++ b/inbox/queue/.extraction-debug/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-international-patent-cliff-is-2026-2028-event-not-2030-creating-geographic-price-bifurcation.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "us-medicaid-coverage-loss-and-glp-1-price-compression-create-inverse-access-dynamics-for-low-income-populations.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-international-patent-cliff-is-2026-2028-event-not-2030-creating-geographic-price-bifurcation.md:set_created:2026-03-20", + "us-medicaid-coverage-loss-and-glp-1-price-compression-create-inverse-access-dynamics-for-low-income-populations.md:set_created:2026-03-20" + ], + "rejections": [ + "glp-1-international-patent-cliff-is-2026-2028-event-not-2030-creating-geographic-price-bifurcation.md:missing_attribution_extractor", + "us-medicaid-coverage-loss-and-glp-1-price-compression-create-inverse-access-dynamics-for-low-income-populations.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-20" +} \ No newline at end of file diff --git a/inbox/queue/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.md b/inbox/queue/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.md index 8094ae2ab..17e3fab96 100644 --- a/inbox/queue/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.md +++ b/inbox/queue/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.md @@ -7,9 +7,13 @@ date: 2026-03-17 domain: health secondary_domains: [] format: news analysis -status: unprocessed +status: enrichment priority: high tags: [glp1, semaglutide, generics, price-compression, india, patent-expiry, ozempic, wegovy] +processed_by: vida +processed_date: 2026-03-20 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -59,3 +63,18 @@ tags: [glp1, semaglutide, generics, price-compression, india, patent-expiry, oze PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Direct challenge to existing KB claim — patent expiration is happening NOW (India: March 20, 2026), not in 2030+. The "inflationary through 2035" claim needs geographic scoping at minimum and may be fundamentally wrong at the system level. EXTRACTION HINT: Extractor should propose a scope qualification or replacement for the existing GLP-1 claim, distinguishing US (patent-protected through 2031-2033) from international (price compression beginning 2026) and system-level (inflationary) from risk-bearing payer level (potentially deflationary by 2028-2030). + + +## Key Facts +- India semaglutide patent expired March 20, 2026 +- 50+ generic brands filed for Indian market launch March 21, 2026 +- Indian branded semaglutide price: ₹8,000-16,000/month (~$95-190) +- Indian generic launch price: ₹3,000-5,000/month (~$36-60), representing 50-60% reduction +- Named Indian generic manufacturers: Dr. Reddy's, Cipla, Sun Pharma (Noveltreat, Sematrinity), Zydus (Semaglyn), OneSource Specialty Pharma +- Semaglutide patents also expire in 2026: Canada, Brazil, Turkey, China +- US semaglutide patents: 2031-2033 +- University of Liverpool production cost analysis: $3/month ($28-140/year) +- Canadian branded Ozempic: ~$400 CAD/month +- Canadian projected generic price: $60-100 CAD/month within 12 months +- Felix Health (Canada) already forming generic Ozempic waitlist +- Oral Wegovy launched January 2026 at $149-299/month vs $1,300+ injectable branded -- 2.45.2 From c404742dae62995a247a64c13d11aef69cdf1adc Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Fri, 20 Mar 2026 04:57:32 +0000 Subject: [PATCH 4/4] auto-fix: strip 2 broken wiki links Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base. --- ...model makes the net cost impact inflationary through 2035.md | 2 +- ...affordability-not-just-clinical-factors-drive-persistence.md | 2 +- 2 files changed, 2 insertions(+), 2 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 958fa002f..19b515005 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -121,7 +121,7 @@ If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg rega ### Additional Evidence (challenge) -*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19* +*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19* Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself. diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index 914b402ef..4efeb5402 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -45,7 +45,7 @@ The Trump Administration deal establishes a $50/month out-of-pocket maximum for ### Additional Evidence (confirm) -*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18* +*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-18* Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects, but the sample is biased toward higher-income employed populations. The fact that even in this relatively advantaged cohort, adherence is the key determinant of cost-effectiveness supports the claim that affordability barriers in lower-income populations would be even more binding. -- 2.45.2